Accessibility StatementSkip Navigation EXTON, Pa., Oct. 27, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the launch of its West Synchronyâ"¢ Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available in Jan ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Daniel Markowitz from Evercore ISI sets a new price target for NYSE:WST at $390, indicating a 26.1% potential increase.WST reports a strong third-quarter performance with adjusted EPS of $1.96, beating estimates by 17.4%.The company raises its full-year EPS outlook to $7.06 to $7.11, driven by strong demand and favorable foreign exchange conditions.West Pharmaceutical Services, Inc. (NYSE:WST) is a leading provider of innovative solutions for injectable drug administration. The company specializes in the de ...

评级与价格目标 - Evercore ISI将公司评级上调至“跑赢大盘”，目标股价从350美元提升至390美元 [1] - 评级调整时公司股价为309.35美元 [1] 2025年第三季度财务业绩 - 调整后每股收益为1.96美元，超出市场预期的1.68美元，实现17.37%的盈利惊喜 [2] - 净销售额达到8.046亿美元，同比增长7.7%，超出预期的7.8793亿美元 [2] 业务部门表现 - 专有产品部门销售额增长至6.475亿美元，同比增长7.7%，有机增长率为5.1% [3] - 合同制造产品部门销售额增长至1.571亿美元，同比增长8.0%，有机增长率为4.9% [3] - 高性能组件业务实现两位数增长，受GLP-1产品需求和高性能组件转化率提升推动 [3] 财务展望与驱动因素 - 公司上调了年度利润预期 [4] - 业绩展望乐观主要源于对GLP-1减肥和糖尿病药物所需组件的强劲需求 [4][6] 股票表现与市场数据 - 公司股价当前为308.33美元，日内涨幅达11.31%，交易区间为300美元至322.34美元 [5] - 过去52周股价最高为352.33美元，最低为187.43美元 [5] - 公司市值约为221.7亿美元，当日纽约证券交易所成交量为996,599股 [5]

Key Points It was a beat-and-raise third quarter for the healthcare services specialist. It experienced broad growth throughout its product and service offerings. 10 stocks we like better than West Pharmaceutical Services › West Pharmaceutical Services (NYSE: WST) published its latest set of quarterly figures early Thursday morning, and investors were pleased to see the company did better than expected. They reacted by pushing the company's share price up by nearly 11%, easily eclipsing the 0.6% ris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Key Takeaways WST's Q3 EPS of $1.96 beat estimates by 17.4%, with revenues up 7.7% year over year.WST's Proprietary Products sales rose 7.7%, driven by 16.3% growth in High-Value Product components.WST lifted full-year EPS view to $7.06-$7.11, citing demand strength and FX-related benefits.West Pharmaceutical Services, Inc. (WST) delivered adjusted third-quarter 2025 earnings per share (EPS) of $1.96, which moved up 5.9% year over year. The figure topped the Zacks Consensus Estimate by 17.4%.The adjustments ...

West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the injectable pharmaceutical packaging and delivery systems company’s third-quarter 2025 earnings surpassed analyst estimates.West Pharmaceutical reported adjusted earnings of $1.96 per share, beating the consensus of $1.68.Net sales of $804.6 million increased 7.7% year over year, with organic growth was 5.0%, beating the consensus of $787.93 million.“Our strength was broad-based, across both our Proprietary Products and Contract M ...

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund despite unusual volatility in the macro environment. The fund returned +8.8% (net) in Q3 compared to +5.5% and +3.8% for the S&P Midcap 400 ETF (MDY) and HFRX Equity Hedge Index, respectively. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025. In its third-quarter 2025 i ...

West Pharmaceutical Services (NYSE:WST) Q3 2025 Earnings Call October 23, 2025 08:00 AM ET Company ParticipantsDaniel Markowitz - Equity Research AssociateEric Green - CEOJohn Sweeney - VP of Investor RelationsBob McMahon - CFOConference Call ParticipantsJustin Bowers - AnalystMatt Etoch - Equity Research AnalystDan Leonard - AnalystDoug Schenkel - Senior Research AnalystMichael Ryskin - Equity Research AnalystLarry Solow - AnalystPatrick Donnelly - Stock AnalystPaul Knight - Equity Research AnalystLuke Ser ...